Dose Intensification of Busulfan in the Preparative Regimen Is Associated with Improved Outcomes: A Phase I/II Controlled, Randomized Study Simrit Parmar,

Slides:

Advertisements

Similar presentations

Outcomes of Adults with Acute Lymphoblastic Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation Li Mei Poon, Amir Hamdi, Rima.

Advertisements

Allogeneic Stem Cell Transplantation (Allo-SCT) for the Treatment of T-Cell Acute Lymphoblastic Leukemia (T-ALL); Evaluation of Minimal Residual Disease.

Amifostine Reduces High-Dose Melphalan Induced Gastro-Intestinal Toxicity in Autologous Hematopoietic Cell Transplant (HCT) for Plasma Cell Myeloma Vinita.

Outcomes of Adults with Acute Lymphoblastic Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation Li Mei Poon, Amir Hamdi, Rima.

Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Low Left Ventricular Ejection Fraction Muzaffar H. Qazilbash, Ali Imran.

Ulas D. Bayraktar, Denái R. Milton, Elizabeth J

CC-486 (Oral Azacitidine) Maintenance Therapy Is Well Tolerated after Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) in Patients with Myelodysplastic.

Intravenous Busulfan Plus Melphalan Is a Highly Effective, Well-Tolerated Preparative Regimen for Autologous Stem Cell Transplantation in Patients with.

Muzaffar H. Qazilbash, MD, Peter Thall, PhD, Patricia S

High-Dose Infusional Gemcitabine Combined with Busulfan and Melphalan with Autologous Stem-Cell Transplantation in Patients with Refractory Lymphoid.

Clofarabine ± Fludarabine with Once Daily i. v

Outcome of Patients with Multiple Myeloma by Ethnicity in the Setting of Autologous Stem Cell Transplant Koji Sasaki, MD, Qaiser Bashir, MD, Nina Shah,

Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia.

Moderate Renal Function Impairment Does Not Affect Outcomes of Reduced-Intensity Conditioning with Fludarabine and Melphalan for Allogeneic Hematopoietic.

T-Cell Acute Lymphoblastic Lymphoma (T-LBL) and Stem Cell Transplantation (SCT): A Comparison of Outcomes with T-Cell Acute Lymphoblastic Leukemia (T-ALL)

Clinical Outcomes of Multiple Myeloma Patients with TP53 Gene Deletion after Autologous Stem Cell Transplantation: The MD Anderson Cancer Center Experience

Results of a Retrospective Single Institution Analysis of Targeted Skeletal Radiotherapy with 166Holmium-DOTMP as Conditioning Regimen for Autologous.

Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes

Long-Term Follow-Up of Patients Who Experienced Graft Failure Postallogeneic Progenitor Cell Transplantation. Results of a Single Institution Analysis

Allogeneic Hematopoietic Cell Transplantation (HCT) Results in Better Time to Next Therapy (TTNT) Than Chemotherapy (CT) in Chronic Lymphocytic Leukemia.

Intravenous Busulfan Plus Melphalan Is a Highly Effective, Well-Tolerated Preparative Regimen for Autologous Stem Cell Transplantation in Patients with.

Outcomes of Patients with Myeloid Malignancies Treated with Allogeneic Hematopoietic Stem Cell Transplantation from Matched Unrelated Donors Compared.

Quantifying the Survival Benefit for Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed Acute Myelogenous Leukemia Paul M. Armistead, Marcos.

Allogeneic Stem Cell Transplantation (Allo-SCT) for the Treatment of T-Cell Acute Lymphoblastic Leukemia (T-ALL); Evaluation of Minimal Residual Disease.

Significance of Persistent Cytogenetic Abnormalities on Myeloablative Allogeneic Stem Cell Transplantation in First Complete Remission Betul Oran, Uday.

Phase II study of autologous transplantation with interleukin-2-incubated peripheral blood stem cells and posttransplantation interleukin-2 in relapsed.

Receiving Information on Fertility- and Menopause-Related Treatment Effects among Women Who Undergo Hematopoietic Stem Cell Transplantation: Changes in.

Similar Transplantation Outcomes for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with Haploidentical versus 10/10 Human Leukocyte Antigen–

Central Nervous System Relapse in Adults with Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation Amir Hamdi, Raya.

David C. Yao, MD, PhD, Paolo Caimi, MD, Hillard M

Fludarabine-Melphalan Conditioning for AML and MDS: Alemtuzumab Reduces Acute and Chronic GVHD without Affecting Long-Term Outcomes Koen Van Besien,

CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes Marcos de Lima, Betul Oran, Richard.

Busulfan-Dependent Hepatotoxicity of Antithymocyte Globulin Formulations During Conditioning for Hematopoietic Stem Cell Transplantation Walter J.F.M.

Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia Fleur M. Aung,

Long-Term Follow-up of Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia:

Kamal Kant Singh Abbi, Junting Zheng, Sean M

A Phase III Study of Infliximab and Corticosteroids for the Initial Treatment of Acute Graft-versus-Host Disease Daniel R. Couriel, Rima Saliba, Marcos.

Impact of t(11;14)(q13;q32) on the Outcome of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma Koji Sasaki, Gary Lu, Rima M. Saliba,

Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing.

Outcome of Patients with Multiple Myeloma with t(4;14) after Autologous Hematopoietic Stem Cell Transplantation Koji Sasaki, MD, Rima Saliba, PhD, Gary.

Biology of Blood and Marrow Transplantation

Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic.

Results of 10-Year Single Center Experience with Pharmacokinetics Directed Intravenous Busulfan, Cyclophosphamide and Etoposide Preparative Regimen in.

Haploidentical Transplantation for Advanced Hematologic Malignancies Using Melphalan-Based Conditioning – Mature Results from a Single Center Sai Ravi.

Early Response to Initial Induction Chemotherapy in Acute Myeloid Leukemia (AML) and Outcomes after Allogeneic Hematopoietic Cell Transplant (HCT) Masumi.

Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas

Biology of Blood and Marrow Transplantation

ASBMT and CBMTG Release Choosing Wisely BMT Recommendations

Resolved Hepatitis B Virus Infection Is Not Associated with Worse Outcome after Allogeneic Hematopoietic Stem Cell Transplantation Carlos A. Ramos, Rima.

Myeloablative Reduced-Toxicity i. v

Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic.

Cytogenetics and Blast Count Determine Transplant Outcomes in Advanced AML Uday R. Popat, MD, Rima Saliba, PhD, Betul Oran, MD, Julianne Chen, BS, Amin.

Comparison of High-Dose Gemcitabine, Busulfan and Melphalan (GEM/BU/MEL) and BEAM in Concurrent Patient Cohorts with Mature T-CELL NON-Hodgkin's Lymphoma.

Allogeneic Stem Cell Transplantation for Myelofibrosis with Leukemic Transformation Stefan O. Ciurea, Marcos de Lima, Sergio Giralt, Rima Saliba, Carlos.

Lymphocyte Recovery Predicts Outcomes in Cord Blood and T Cell–Depleted Haploidentical Stem Cell Transplantation Stefan O. Ciurea, Victor Mulanovich,

Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia Patients Mithun Vinod Shah, Rima M.

Blood and Marrow Transplant Handbook

Outcomes of Haploidentical Stem Cell Transplantation for Lymphoma with Melphalan- Based Conditioning Jonathan E. Brammer, Issa Khouri, Sameh Gaballa,

Muzaffar H. Qazilbash, Rima M

Dose Intensification of Busulfan in the Preparative Regimen is Associated with Improved Survival: A Phase I/II Controlled, Randomized Study Simrit Parmar,

Long-term Outcome of Hodgkin Disease Patients Following High-Dose Busulfan, Etoposide, Cyclophosphamide, and Autologous Stem Cell Transplantation—A Similar.

Improved Early Outcomes Using a T Cell Replete Graft Compared with T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation Stefan O. Ciurea,

Mammen Chandy Biology of Blood and Marrow Transplantation

Autologous Stem Cell Transplantation for Refractory or Poor-Risk Relapsed Hodgkin's Lymphoma: Effect of the Specific High-Dose Chemotherapy Regimen on Outcome

Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation Daniel R Couriel,

In Memoriam: E. Donnall Thomas

Daniel Couriel, Chitra Hosing, Rima Saliba, Elizabeth J

Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin.

Once Daily i. v. Busulfan and Fludarabine (i. v

Results of Allogeneic Double Umbilical Cord Blood Transplantation for Relapsed and Refractory Hodgkin Lymphoma Philip A. Thompson, MBBS, FRACP, FRCPA,

Presentation transcript:

Dose Intensification of Busulfan in the Preparative Regimen Is Associated with Improved Outcomes: A Phase I/II Controlled, Randomized Study Simrit Parmar, Gabriela Rondon, Marcos de Lima, Peter Thall, Roland Bassett, Paolo Anderlini, Partow Kebriaei, Richard E. Champlin, Sergio A. Giralt Biology of Blood and Marrow Transplantation Volume 19, Issue 2, (February 2013) DOI: 10.1016/j.bbmt.2012.11.443 Copyright © 2013 Terms and Conditions

Figure 1 Biology of Blood and Marrow Transplantation 2013 19, DOI: (10.1016/j.bbmt.2012.11.443) Copyright © 2013 Terms and Conditions